Sujal Ghosh

Dr. Sujal Ghosh


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2025 in Journal of Human Immunity
Verified
Journal Article
Open access
GKGerhard Kindle
Gerhard Kindle
MAMickaël Alligon
Mickaël Alligon
MAMichael H. Albert
Michael H. Albert
MBMatthew Buckland
Matthew Buckland
JEJ. David Edgar
J. David Edgar
MSMarkus G. Seidel
Markus G. Seidel
The European Society for Immunodeficiencies patient registry (ESID-R), established in 1994, is one of the world’s largest databases on inborn errors of immunity (IEI). IEI are genetic disorders predisposing patients to infections, autoimmunity, inflammation, allergies, and malignancies. Treatments include antimicrobial therapy, immunoglobulin replacement, immune modulation, stem cell transplantation, and gene therapy. Data from 194 centers in 33 countries capture clinical manifestations and treatments from birth onward, with annually expected updates. This report reviews the ESID-R’s structure, data content, and impact. The registry includes 30,628 patient datasets (aged 0–97.9 years; median follow-up: 7.2 years; total 825,568.2 patient-years), with 13,550 cases in 15 sub-studies. It has produced 84 peer-reviewed publications (mean citation rate: 95). Findings include real-world observations of IEI diagnoses, genetic causes, clinical manifestations, treatments, and survival trends. The ESID-R fosters global collaboration, advancing IEI research and patient care. This report highlights the key role of the multinational ESID-R, led by an independent medical society, in evidence-based discovery.

8 May 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
SGSujal Ghosh
Sujal Ghosh
IDIngo Drexler
Ingo Drexler
SBSanil Bhatia
Sanil Bhatia
HAHeiko Adler
Heiko Adler
AGAndrew R. Gennery
Andrew R. Gennery
ABArndt Borkhardt
Arndt Borkhardt
Patients with primary immunodeficiency can be prone to severe Epstein–Barr virus (EBV) associated immune dysregulation. Individuals with mutations in the interleukin-2-inducible T-cell kinase (ITK) gene experience Hodgkin and non-Hodgkin lymphoma, EBV lymphoproliferative disease, hemophagocytic lymphohistiocytosis, and dysgammaglobulinemia. In this review, we give an update on further reported patients. We believe that current clinical data advocate early definitive treatment by hematopoietic stem cell transplantation, as transplant outcome in primary immunodeficiency disorders in general has gradually improved in recent years. Furthermore, we summarize experimental data in the murine model to provide further insight of pathophysiology in ITK deficiency.

1 August 2009 in Pediatric Research
Verified
Journal Article
Closed access
PDF file
SGSujal Ghosh
Sujal Ghosh
OFOliver Feyen
Oliver Feyen
AJAhmad Fasel Jebran
Ahmad Fasel Jebran
KHKirsten Huck
Kirsten Huck
MJMartin Jetzek-Zader
Martin Jetzek-Zader
TNTim Niehues
Tim Niehues

1 May 2014 in Clinical Immunology
Verified
Journal Article
Closed access
SGSujal Ghosh
Sujal Ghosh
FSFriedhelm R. Schuster
Friedhelm R. Schuster
OAOrtwin Adams
Ortwin Adams
FBFlorian Babor
Florian Babor
ABArndt Borkhardt
Arndt Borkhardt
RMRoland Meisel
Roland Meisel

23 September 2021 in Cancers
Verified
Journal Article
Open access
PDF file
CLCiro Novaes Rosa Lino
Ciro Novaes Rosa Lino
SGSujal Ghosh
Sujal Ghosh
Epstein–Barr Virus (EBV) is a ubiquitous virus affecting more than 90% of the world’s population. Upon infection, it establishes latency in B cells. It is a rather benign virus for immune-competent individuals, in whom infections usually go unnoticed. Nevertheless, EBV has been extensively associated with tumorigenesis. Patients suffering from certain inborn errors of immunity are at high risk of developing malignancies, while infection in the majority of immune-competent individuals does not seem to lead to immune dysregulation. Herein, we discuss how inborn mutations in TNFRSF9, CD27, CD70, CORO1A, CTPS1, ITK, MAGT1, RASGRP1, STK4, CARMIL2, SH2D1A, and XIAP affect the development, differentiation, and function of key factors involved in the immunity against EBV, leading to increased susceptibility to lymphoproliferative disease and lymphoma.

23 February 2012 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
SGSujal Ghosh
Sujal Ghosh
FSFriedhelm R. Schuster
Friedhelm R. Schuster
VBVera Binder
Vera Binder
TNTim Niehues
Tim Niehues
SBStephan E. Baldus
Stephan E. Baldus
RMRoland Meisel
Roland Meisel